Pfizer-BioNTech say booster dose provides high level of protection against omicron variant

A vaccinator attracts a Pfizer-BioNTech coronavirus illness (COVID-19) pediatric vaccine in Lansdale, Pennsylvania, U.S., December 5, 2021.

Hannah Beier | Reuters

Three doses of Pfizer and BioNTech’s vaccine present a excessive stage of safety in opposition to the omicron variant of the virus that causes Covid-19, the businesses introduced on Wednesday.

A booster shot of the vaccine will increase antibody safety 25-fold in contrast with the preliminary two-dose collection, based on a preliminary lab examine. A 3rd shot provides a excessive stage of safety corresponding to the impact of two doses in opposition to the unique pressure of the virus.

The businesses mentioned they are going to have a vaccine that particularly targets omicron accessible by March 2022.

“Though two doses of the vaccine should supply safety in opposition to extreme illness brought on by the Omicron pressure, it is clear from these preliminary information that safety is improved with a 3rd dose of our vaccine,” Pfizer CEO Albert Bourla mentioned in a joint assertion with BioNTech.

“Making certain as many individuals as attainable are absolutely vaccinated with the primary two dose collection and a booster stays the perfect plan of action to stop the unfold of COVID-19,” he mentioned.

Source link

Related posts

Apple’s stock usually beats the market from July-September

WDC TV Staff

Robinhood says restrictions on GameStop due to tenfold increase in clearinghouse deposit requirements

WDC TV Staff

Profit at bid target Morrisons falls 37% on Covid hit

WDC TV Staff